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Abstract
Despite suggestions that higher serum magnesium (Mg) levels are associated with
improved outcome, the association with mortality in European hemodialysis (HD) patients
has only scarcely been investigated. Furthermore, data on the association between serum
Mg and sudden death in this patient group is limited. Therefore, we evaluated Mg in a post-
hoc analysis using pooled data from the CONvective TRAnsport STudy (CONTRAST,
NCT00205556), a randomized controlled trial (RCT) evaluating the survival risk in dialysis
patients on hemodiafiltration (HDF) compared to HD with a mean follow-up of 3.1 years.
Serum Mg was measured at baseline and 6, 12, 24 and 36 months thereafter. Cox propor-
tional hazards models, adjusted for confounders using inverse probability weighting, were
used to estimate hazard ratios (HRs) of baseline serum Mg on all-cause mortality, cardio-
vascular mortality, non-cardiovascular mortality and sudden death. A generalized linear
mixed model was used to investigate Mg levels over time. Out of 714 randomized patients,
a representative subset of 365 (51%) were analyzed in the present study. For every
increase in baseline serum Mg of 0.1 mmol/L, the HR for all-cause mortality was 0.85 (95%
CI 0.77–94), the HR for cardiovascular mortality 0.73 (95% CI 0.62–0.85) and for sudden
death 0.76 (95% CI 0.62–0.93). These findings did not alter after extensive correction for
potential confounders, including treatment modality. Importantly, no interaction was found
between serum phosphate and serum Mg. Baseline serum Mg was not related to non-car-
diovascular mortality. Mg decreased slightly but statistically significant over time (Δ -0.011
mmol/L/year, 95% CI -0.017 to -0.009, p = 0.03). In short, serum Mg has a strong, indepen-
dent association with all-cause mortality, cardiovascular mortality and sudden death in
European HD patients. Serum Mg levels decrease slightly over time.
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Introduction
Despite continuous research as well as improvements in treatment, mortality among hemodial-
ysis (HD) patients remains unacceptably high [1], of which a large proportion can be attributed
to cardiovascular causes [2]. Magnesium (Mg) is the fourth most abundant cation in the
human body. Its role, however, has been neglected in HD patients. Mg is involved in a wide
variety of biological processes [3], such as inhibition of vascular calcification [4–6] and cation
fluxes in cardiomyocytes [7].
In non-renal cohorts, low serumMg is associated with atherosclerotic lesions [8], coronary
disease [9], and sudden death [10]. Furthermore, data suggests that a higher Mg intake is asso-
ciated with decreases of aortic and carotid arterial calcification scores [11,12].
In Japanese HD patients, serumMg was recently shown to be inversely associated with all-
cause, cardiovascular and non-cardiovascular mortality [13,14]. In addition, these researchers
demonstrated that Mg levels modify the risk of serum phosphate on adverse clinical outcomes
in the same large cohort, i.e. a significant decrease in cardiovascular mortality risk in patients
with a high phosphate when serum Mg levels increase [15]. Most of these associations were
identified in the Japanese population, which is fundamentally different from western people
with regard to medical history, such as dialysis vintage or transplantation rate [16,17], and die-
tary habits, including Mg intake [18]. Nevertheless, two recent American studies and a Portu-
guese study confirmed the inverse association between serumMg and all-cause mortality in
HD patients. However, generalizability from both Japanese and American studies to European
HD patients warrants confirmation of the findings. Furthermore, the Portuguese study is lim-
ited by a binary approach of the serum Mg level and a hypermagnesemic population
(mean serum Mg 1.36 mmol/L versus a reference range of 0.70–1.00 mmol/L in the Nether-
lands) [19–21].
Thus, the question arises whether the positive association between serumMg and survival
can be confirmed in a large, well-defined European HD cohort. Furthermore, presently, limited
data are available on the association between serumMg and sudden death in HD patients as
well as data concerning serumMg levels over time. To elucidate these issues, we analysed sam-
ples of patients from the CONvective TRAnsport STudy (CONTRAST).
Materials and Methods
CONTRAST was conducted in accordance with the declaration of Helsinki and Good Clinical
Practice guidelines and was approved by the central medical ethics review board of VU Univer-
sity Medical Center, Amsterdam, the Netherlands (METC VUmc 2003/97). The design and
methods of the CONTRAST study (NCT00205556) have been described elsewhere [22,23]. In
brief, CONTRAST was an RCT designed to evaluate the effect of postdilution online hemodia-
filtration (HDF) compared to low-flux HD on all-cause mortality and cardiovascular events.
From 2004–2010, 714 patients were enrolled in 29 dialysis facilities in 3 countries (the Nether-
lands [n = 26], Canada [n = 2] and Norway n = 1]). Adult (18 years) end-stage kidney disease
(ESKD) patients were eligible when treated chronically (2 months) with HD two or three
times per week. Furthermore, patients had to be able to understand the study procedures and
be willing to provide informed consent. Exclusion criteria were severe incompliance to dialysis
prescription, treatment with HDF or high-flux HD in the 6 months preceding randomization,
participation in another clinical intervention trial evaluating cardiovascular outcome or a life
expectancy below 3 months due to a non-renal disease. Written informed consent was obtained
from all participants prior to randomization.
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Patients
In a subset of centers in which it was logistically feasible to collect and store blood samples for
non-routine assessment (only Dutch and Norwegian patients), serum samples were drawn
prior to dialysis and stored at -80 degrees Celsius for future determinations. These samples
were collected at baseline and 6, 12, 24 and 36 months thereafter. Mg (total serum Mg++) was
measured in 2014 in these samples in a central laboratory (VU University Medical Center,
Amsterdam, the Netherlands) photometrically through the decrease in xylidyl blue absorption.
Participants from CONTRAST were included in the present analysis if at least baseline serum
Mg had been measured. Data from the two treatment arms (low-flux HD and postdilution
online HDF) were pooled for this study.
Data collection
Demographic data, medical history, dialysis characteristics, routine laboratory measurements
and medication use were recorded at baseline. Subsequently, routine laboratory measurements,
medication use and dialysis characteristics were registered every three months thereafter. In
both study arms, patients were treated with bicarbonate-containing ultrapure dialysis fluid, of
which the Mg concentration is usually 0.5 mmol/L.
Follow-up
Patients were followed from randomization until death or end of the study. Clinical events
were continuously monitored. There was no loss to follow-up as patients who stopped the ran-
domized treatment, for example due to renal transplantation, a switch to peritoneal dialysis or
moving to a non-participating center, were still followed for mortality. Cardiovascular death
was defined as death due to myocardial infarction, rupture of an aneurysm, sudden death, ter-
minal heart failure or either hemorrhagic or ischemic stroke. Sudden death was defined as
either certain sudden death (death within one hour after onset of symptoms as verified by a
witness) or probable sudden death (death within 24 hours after onset of symptoms as verified
by a witness or found dead by a witness). An independent Endpoint Adjudication Committee
reviewed source documentation of all clinical outcomes.
Statistical analyses
As the number of one of the outcome parameters was limited (sudden death; n = 24), an
inverse probability weighted marginal structural model (IPWMSM) with Mg as continuous
exposure was used to be able to correct for more confounders than allowed by conventional
adjustment for confounding by regression analysis [24]. Using the R-package ‘ipw’, for each
individual weights were estimated based on information of various confounders (https://cran.
r-project.org/web/packages/ipw/index.html). Weighting each participants by his or her weight
then results in a weighted population in which Mg levels are independent of confounding val-
ues. Next, weighted Cox proportional hazards models were fitted with a robust variance esti-
mator to estimate hazard ratios (HRs) per 0.1 mmol/L increase in serumMg. Five models were
fitted: a crude model and four models adjusted for a priori selected potential confounders. In
the first adjusted model, HRs were corrected for age, sex, dialysis vintage, and residual kidney
function. The second model was corrected for the confounders in model 1 plus diabetes, BMI,
history of cardiovascular disease, and dialysis modality (HD/HDF). In the third model, HRs
adjusted for the potential confounders of model 2 plus serum albumin, the mean pre-dialytic
systolic blood pressure, and treatment time were estimated. The last model calculated HRs cor-
rected for the confounders in model 3 plus serum calcium, serum parathyroid hormone and
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serum phosphate. To check whether the results of the analysis adjusting with an IPWMSM are
valid, as a comparison, Cox proportional hazards models were also fitted with all confounders
included as covariates into the model. For all-cause mortality, a sufficient number of events
occurred (n = 137) to be able to appropriately fit a multivariable Cox regression model, allow-
ing this model to be compared with the IPWMSMmodel. The assumptions of the Cox propor-
tional hazards models, i.e. proportional hazards and a linear association between Mg and
mortality hazard, were checked with Martingale and Schoenfeld residuals, respectively, and
appeared to hold.
Possible interaction between serumMg and serum phosphate in relation to clinical outcome
was also explored [15]. Cox regression analysis was used to fit twelve models (4 categories as
described below and 3 end points: all-cause mortality, cardiovascular mortality and sudden
death). First, three models were fitted with serum Mg as a continuous variable, serum phos-
phate as a dichotomous variable and an interaction term between these variables. Hereafter,
similar models were fitted using serumMg as a dichotomous variable, serum phosphate as a
continuous variable and an interaction term. Third and fourth, models with both variables as
continuous values with an interaction term and both variables as dichotomous variables with
an interaction term were fitted, respectively.
For the longitudinal data on Mg evolution, a generalized linear mixed model was used with
either a random intercept or a random slope plus a random intercept, based on the lowest
Aikaike’s Information Criterion. As the time between measurements was unequal (i.e. either 6
or 12 months), a continuous autoregressive covariance matrix was used. Lastly, the entire
cohort was divided into quartiles based on their baseline Mg concentration. The course over
time from these 4 groups was plotted to visualize any possible regression to the mean. Statisti-
cal analyses were performed using either the statistical software package SPSS 20.0 (IBM Inc.,
IL, USA) or RStudio (RStudio Inc., version 0.98.932).
Sensitivity analysis
As a sensitivity analysis, the aforementioned analyses were repeated with censoring of patients
at the time of treatment discontinuation due to, for example, a switch to peritoneal dialysis,
moving to a non-participating center or renal transplantation. Again, crude and adjusted Cox
proportional hazards models were used to calculate HRs per 0.1 mmol/L increase in serumMg.
Results
Patients and magnesium distribution
Out of the 714 patients included in CONTRAST, baseline serum Mg was available for 365
Dutch and Norwegian patients. Baseline characteristics of both the entire cohort and the inves-
tigated cohort are shown in Table 1. No marked differences were observed between these
groups. In the investigated patients, mean age was 63.5±13.8 years and 61.9% were male.
Mean serumMg was 0.98±0.13 mmol/L (Fig 1). Of note, the baseline Mg value of patients ran-
domized to HD was slightly lower than in patients randomized to HDF (mean 0.95±0.17 and
1.00±0.19 mmol/L, respectively, p for difference = 0.01). Mean spKt/Vurea was 1.39±0.20 per
dialysis session and mean follow-up was 3.06±1.76 years.
Magnesium and mortality outcomes
A linear association was found between serum Mg and all-cause mortality risk with a HR of
0.85 (95% CI 0.77–0.94), indicating a significant reduction in all-cause mortality risk of 15%
per 0.1 mmol/L increase in serumMg. For cardiovascular mortality, the association was even
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stronger: crude HR 0.73 (95% CI 0.62–0.85) per 0.1 mmol/L higher serumMg concentration.
The survival risk for cardiovascular mortality per Mg quartile was visualized with a Kaplan-
Meier curve (Fig 2). A similar reduction in hazard for sudden death was found (crude HR 0.76
[95% CI 0.62–0.93]). Importantly, subsequent models adjusting for various upfront deter-
mined potential confounders did not materially change the strength of any of the associations.
Details of the weighted Cox proportional hazards models are shown in Table 2. Results from
the multivariable Cox regression model as a sensitivity analysis for the IPWMSM are shown in
S1 Table. As can be seen from the comparison between Table 2 and S1 Table, the results from
the different models were similar, suggesting that the IPWMSM is at least equally as valid as
the conventional method to control for confounding. The results of the sensitivity analysis are
shown in S2 Table, which show similar results. Importantly, none of the models exploring
interaction between serumMg and phosphate showed a significant result (p-values0.32).
Table 1. Baseline Patient Characteristics.
Determinant Investigated cohort (n = 365) Entire cohort (n = 714)
Age (years) 63.5 (13.8) 64.1 (13.7)
Sex (male) 226 (61.9%) 445 (62.3%)
BMI (kg/m2) 24.9 (4.9) 24.7 (4.8)
Region (NL) 350 (95.9%) 597 (83.6%)
Diabetes 76 (20.8%) 170 (23.8%)
Cardiovascular disease 163 (44.7%) 313 (43.8%)
Residual kidney function* 212 (58.1%) 376 (52.7%)
Previous renal transplantation 41 (11.2%) 78 (10.9%)
Phosphate (mmol/L) 1.67 (0.52) 1.64 (0.49)
Albumin (g/L)# 39.9 (4.0) 40.4 (3.8)
Cholesterol (mmol/L) 3.66 (0.99) 3.68 (0.96)
Creatinine (μmol/L) 864 (253) 861 (255)
Hemoglobin (g/L) 119 (13) 118 (13)
Magnesium (mmol/L) 0.98 (0.18) NA
RAS inhibitor¶ 201 (55.1%) 351 (49.2%)
Beta-blocker 210 (57.5%) 381 (53.4%)
Calcium antagonist 125 (34.2%) 230 (32.2%)
Statin 186 (51.0%) 369 (51.7%)
Platelet aggregation inhibitor 103 (28.2%) 240 (33.6%)
Dialysis vintage (years) 1.8 (0.9–3.4) 2.0 (1.0–4.0)
spKt/Vurea 1.39 (0.20) 1.40 (0.22)
Assigned to HDF treatment 181 (49.6%) 358 (50.1%)
Data are presented as mean (standard deviation), median (interquartile range) or number (percentage),
when appropriate
* Deﬁned as diuresis >100 mL/24h
# Bromocresol green values
¶ Prescription of either an ACE inhibitor or an ATII antagonist
Abbreviations: BMI = Body Mass Index; NL = the Netherlands; PTH = parathyroid hormone;
CRP = C-Reactive Protein; RAS = renin-angiontensin system; HDF = hemodiaﬁltration; NA = not applicable
doi:10.1371/journal.pone.0143104.t001
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Magnesium evolution over time
From the generalized linear mixed model, it was shown that on average serumMg decreased
over time in these patients (Δ -0.011 mmol/L/year, 95% CI -0.017 to -0.009, p = 0.03). Longitu-
dinal data as stratified by baseline serumMg quartiles were plotted (Fig 3). As can be seen from
this graph, the serumMg concentration quartile slopes do not cross during follow-up.
Discussion
In the present study, a strong and inverse association was found between baseline serumMg
and all-cause mortality, cardiovascular mortality and sudden death. The risk on these adverse
events drops linearly per 0.1 mmol/L higher serum Mg. Importantly, extensive correcting for
potential confounders did not at all mitigate the strength of any association. The large number
of measured confounders that was adjusted for suggest that the impact of confounding on the
association was probably small. Furthermore, we showed that serum Mg in HD patients
decreases slightly over time. As serumMg in dialysis patients depends on intake, uptake, resid-
ual kidney function and the Mg concentration of the dialysis fluid, this important risk factor is
potentially modifiable. As such, the current study sets the stage for prospective intervention
Fig 1. Distribution of baseline serummagnesium (mmol/L).
doi:10.1371/journal.pone.0143104.g001
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trials to test the hypothesis that the high mortality rate in HD patients can be improved by
increasing their serumMg concentration.
An observational study on 515 Japanese HD patients found that in an adjusted time-to-
event analysis, the HR was 0.49 (95% CI 0.24–0.98) per 1.0 mg/dL (0.41 mmol/L) higher serum
Mg [13]. In that study, the effect was most pronounced for non-cardiovascular mortality,
which is opposite to previous findings of studies in non-renal patients and to the current study.
A more recent logistic regression analysis from Japan on almost 150000 HD patients showed
that the fifth sextile of Mg (2.8–3.1 mg/dL [1.15–1.27 mmol/L]) had the lowest odds on both
cardiovascular and non-cardiovascular mortality [14]. A large American study found an almost
linear association between serumMg and death [19], and another American cohort study con-
firmed the inverse relation between serumMg and survival [20]. Lastly, a Portuguese study
Fig 2. Cardiovascular survival curves stratified by quartiles of baseline serummagnesium. Kaplan-Meier curves of cardiovascular survival as
stratified by baseline serummagnesium:0.85 (cat 1, n = 92); 0.85–0.96 (cat 2, n = 95); 0.96–1.08 (cat 3, n = 87); >1.08 (cat 4, n = 91).
doi:10.1371/journal.pone.0143104.g002
Magnesium and Mortality in Hemodialysis
PLOS ONE | DOI:10.1371/journal.pone.0143104 November 23, 2015 7 / 13
found similar results in a hypermagnesemic cohort where serumMg was dichotomized [21].
Some of these findings differ from our study, which may be explained by adjustment for other
covariates, different population characteristics, or both. Oriental and occidental dietary habits,
including Mg intake, differ [18] and probably influence outcome. Furthermore, the transplan-
tation rate in Japan is much lower compared to Europe [17]. As in Europe the younger and
healthier patients tend to get transplanted, an older population remains on dialysis in this geo-
graphic area. Consequently, the dialysis population in Japan is generally younger and in a bet-
ter shape when compared to the European dialysis population. These hypotheses are supported
by the fact that in the first Japanese study, 103/515 patients died (20%) over a mean follow-up
of 51 months, while in our study 137/365 patients died (37.5%) over a mean follow-up of 37
months. Furthermore, in the large database-driven study of HD patients from Japan, mean
serumMg was 2.61±0.52 mg/dL (1.07±0.21 mmol/L), whereas the mean serum Mg concentra-
tion was 0.98±0.13 mmol/L at baseline in our study. Finally, the Mg concentration in the
highest sextile from the study in Japan (above 3.1 mg/dL [1.27 mmol/L]) was rare in our popu-
lation. Therefore, we cannot investigate whether the hazard for survival is lower at the higher
extreme end of Mg concentrations in western HD populations as well. Our findings concerning
survival are in line with the recent studies on 27544 and 9359 prevalent and incident American
HD patients [19,20] as well as the findings from João Matias et al [21].
The strong association between Mg and cardiovascular mortality raises the question of the
possible biological mechanisms involved. In patients with chronic kidney disease (CKD), the
transformation of vascular smooth muscle cells (VSMCs) to an osteochrondrogenic phenotype
is involved in arterial medial calcification (AMC) [25], increasing arterial stiffness. Patients
with AMC have an impaired prognosis compared to patients without arterial calcification
[26,27]. In ESKD, it has been suggested that a mild hypermagnesemia may retard the develop-
ment of arterial calcification [4]. In bovine VSMC, calcification induced by ß-glycerophosphate
could be prevented by co-incubation with Mg in a dose-dependent matter. Furthermore, with
higher Mg levels, an inhibited expression of osteogenic proteins, apoptosis and further progres-
sion of already established calcification was found [5]. Moreover, in the presence of Mg, less
calcification of aortic segments of rats was observed despite increasing phosphate levels [6], an
effect that was confirmed in human aorta VSMCs [28] and in line with the recent finding of a
Table 2. Association between serumMg and outcomes: results of weighted Cox proportional hazardsmodels#.
All-cause mortality (137
events)
Cardiovascular mortality (43
events)
Non-cardiovascular mortality (94
events)
Sudden death (24
events)
Crude* 0.85 (0.77–0.94)& 0.73 (0.62–0.85)& 0.91 (0.81–1.01) 0.76 (0.62–0.93)&
Model 1^ 0.87 (0.79–0.96)& 0.74 (0.64–0.86)& 0.93 (0.83–1.04) 0.77 (0.64–0.94)&
Model 2$ 0.85 (0.77–0.94)& 0.73 (0.62–0.86)& 0.91 (0.81–1.01) 0.77 (0.62–0.94)&
Model 3¶ 0.88 (0.79–0.98)& 0.74 (0.64–0.86)& 0.93 (0.83–1.05) 0.79 (0.66–0.94)&
Model 4§ 0.88 (0.78–0.99)& 0.73 (0.62–0.85)& 0.93 (0.82–1.06) 0.78 (0.66–0.92)&
Results presented as hazard ratios (HRs [95% conﬁdence intervals]) per 0.1 mmol/L higher baseline serum magnesium concentration. Adjusted for
confounders described below using an #inverse probability weighted marginal structural model
* Crude model (n = 365)
^ Adjusted for age, sex, dialysis vintage and residual kidney function (n = 365)
$ Adjusted as in model 1 plus diabetes mellitus, BMI, history of cardiovascular disease and dialysis modality (n = 351)
¶Adjusted as in model 2 plus serum albumin, mean pre-dialytic systolic blood pressure and treatment time (n = 339)
§ Adjusted as in model 3 plus serum calcium, serum parathyroid hormone and serum phosphate (n = 334)
& indicates a signiﬁcant difference in adverse event risk (p<0.05)
doi:10.1371/journal.pone.0143104.t002
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reduced cardiovascular mortality risk with increasing Mg in patients with a high phosphate
level [15]. Possibly, reductions in the phosphate-induced Wnt/ß-catenin pathway activation
partly drives these findings [29]. In this respect, however, it should be noted that in contrast to
the Japanese findings in our cohort no interaction between Mg and phosphate was found,
which would necessitate further research on the possible role of phosphate in the association
between serum Mg and clinical outcome.
Recent evidence showed a positive association between Mg and flow-mediated dilatation
(FMD), a measurement of endothelial functioning, in CKD patients, which is consistent with
the negative association between Mg and vascular stiffening [30]. Lastly, a double-blind
Fig 3. Serummagnesium over time stratified by baseline serummagnesium quartiles. Serummagnesium concentration over time with 95%
confidence intervals at baseline and 6, 12, 24 and 36 months thereafter, as stratified by quartiles of baseline serummagnesium:0.85 (cat 1, n = 92); 0.85–
0.96 (cat 2, n = 95); 0.96–1.08 (cat 3, n = 87); >1.08 (cat 4, n = 91).
doi:10.1371/journal.pone.0143104.g003
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placebo-controlled RCT of non-renal patients with coronary artery disease (CAD) showed that
supplementation of Mg improved FMD [31]. Altogether, Mg may play a protective role in the
process of vascular calcification, which could be an explanation of the inverse association
between cardiovascular mortality and serumMg in this analysis.
Interestingly, we also found an association between serumMg and sudden death, the single
most important cause of death in western dialysis populations. These findings are in line with a
previous study investigating sudden death in a HD cohort with a follow-up of 1 year [19]. In a
double-blind, placebo-controlled RCT of Mg supplementation in CAD patients, an improve-
ment in exercise tolerance and a decrease in ischemic ST-segment changes was observed in the
intervention group [31]. In vitro, vasodilatation decreased in coronary segments in the absence
of Mg and improved again when Mg was replenished. Blockade of nitric oxide (NO) release
was suggested as the causal mechanism [32]. Lastly, Mg plays an essential role in the de- and
repolarisation of cardiac smooth muscle cells [7]. Hence, it is appealing to speculate that Mg
critically influences heart rhythm stability.
As can be seen from our results, serum Mg decreased statistically significant with 0.011
mmol/L/year. However, whether this decrease is clinically relevant is at least debatable given
the fact that this decrease per year is only 10% of the difference in serumMg concentration
that was associated with survival in this cohort. Importantly, as can be seen from Fig 3, patients
in the upper range of serumMg remain in the upper region. Hence, the rate of change found
was not the result of regression to the mean.
As mentioned, Mg supplementation may improve clinical outcome. In many countries, a
Mg dialysis fluid concentration of 0.5 mmol/L (1.0 mEq/L) is standard and this level could eas-
ily be increased. Furthermore, dietary advices [12] or prescription of Mg-containing phosphate
binders [33,34] are other potential options to increase a patients’ Mg level. Obviously, the Mg
concentration has to be carefully monitored in such interventions because our data cannot
prove safety of very high Mg levels.
The main strengths of the present study are the relative long follow-up, the precise and pro-
spective collection of data, including Mg and follow-up of subjects that left the original study,
and the review of end point source documentation for all primary outcomes. Fourth, the serial
measurements of Mg in a central laboratory increases the reliability of the Mg measurement.
Furthermore, the validity of the Cox regression models adjusted with an IPWMSM was
checked in the model for all-cause mortality. From this multivariable analysis, the validity of
the statistical model used is underscored. Lastly, the sensitivity analysis with censoring at the
time of treatment discontinuation increases the robustness of our findings. A limitation is the
availability of baseline serum Mg in only half the patients from the CONTRAST cohort due to
logistical constraints. Even though the baseline characteristics appear similar between the
entire cohort and the investigated cohort, a selection bias cannot be fully excluded. Second,
given the observational nature of the present study, no causal relations can be drawn from this
analysis as correction for unknown or unmeasured confounding is impossible. Given the asso-
ciation between serumMg and sudden death, the absence of serum potassium in the adjusted
models necessitates exploration of this particular finding in an external cohort. Furthermore,
confounding by healthy dietary habits should be considered. However, it may be possible that
beneficial effects of dietary habits are in fact driven by Mg itself. In this respect, it should also
be noted that no correction was able to attenuate the considerable association between Mg and
mortality. Lastly, the association between baseline serumMg and sudden death seems peculiar
since the time between measurement and event may be several years. However, as serumMg
did not materially change over time as was shown by linear mixed models and visualized in Fig
3, our findings seem reliable. Nonetheless, a future prospective investigation should study Mg
levels closer to an event to confirm our findings.
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In short, we found a strong, independent association between serumMg and all-cause mor-
tality, cardiovascular mortality and sudden death in a western HD cohort. Furthermore, serum
Mg in HD patients decreases slightly over time, but in view of the very small quantity of the
decrease, the clinical relevance of this rate of change is uncertain. Future research should inves-
tigate determinants of serumMg and determinants of its course over time. Furthermore, the
promising potential causal mechanisms underlying this association are interesting topics for
future research. Mg supplementation, either orally or by modifying Mg content of the dialysis
fluid, appears to be an easy tool to perform such trials.
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